MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Public ClinicalTrials.gov record NCT06191965. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double Blind, Randomized, Placebo-Controlled Study of MitoQ as Adjunctive Treatment for Patients With Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Study identification
- NCT ID
- NCT06191965
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 100 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 35 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2024
- Primary completion
- Jan 30, 2027
- Completion
- Jan 30, 2027
- Last update posted
- Sep 24, 2025
2024 – 2027
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale School of Medicine | New Haven | Connecticut | 06519 | Not yet recruiting |
| McLean Hospital | Belmont | Massachusetts | 02478 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Cognitive Impairment trials
Other public records listing Cognitive Impairment. Sorted by last update posted; newest first. Not a recommendation.
- NCT07788755: NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia Not yet recruiting
- NCT07220798: Improving Self-Care of Caregivers of Adults in Homecare With Heart Failure and Cognitive Impairment Recruiting
- NCT06182995: Anticipating Decline and Providing Therapy Active, not recruiting
- NCT05431192: Mind Your Heart-II Active, not recruiting
- NCT07547319: Effects of Accelerated rTMS on Cognitive Function Recruiting
- NCT04520139: Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06191965, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06191965 live on ClinicalTrials.gov.